BioCentury
ARTICLE | Clinical News

Phase II PAH readout sinks Eiger shares

January 16, 2018 7:51 PM UTC

Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) lost $7.90 (49%) to $8.10 Tuesday after discontinuing development of ubenimex to treat pulmonary arterial hypertension. The company made the decision after the product missed the primary endpoint in the Phase II LIBERTY trial in the indication.

Eiger will continue development of the small molecule leukotriene A4 hydrolase (LTA4H) and arginyl aminopeptidase (RNPEP; AP-B) inhibitor to treat lymphedema. Data from the Phase II ULTRA trial of ubenimex to treat primary and secondary lymphedema are expected next half...